GLP-1 Market
LLY $1311.66 ▲ +3.2% NVO $39.63 ▲ +1.5% PFE $30.36 ▲ +1.7% VKTX $25.81 ▼ -2.2% KLRA $13.23 ▲ +2.4% GPCR $22.07 ▲ +0.3% RHHBY $59.11 ▼ -0.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Zenagamtide

Company
Novo Nordisk A/S
Mechanism
Mechanism not yet reported
Route
Injectable
Recruiting trials
6 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

6 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 22, 2026

Find a Clinical Trial Near Me

See recruiting studies for Zenagamtide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07668414

    A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

    Not yet reported Novo Nordisk A/S 650 participants Est. completion 2028-10-10 45 sites Added to GLP-1
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Recruiting NCT NCT07720271

    AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

    Not yet reported Novo Nordisk A/S 950 participants Est. completion 2028-08-22 41 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Recruiting NCT NCT07797335

    AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

    Not yet reported Novo Nordisk A/S 1778 participants Est. completion 2028-09-20 330 sites Stand-alone
    Type 2 diabetes Other conditions: Cardiovascular Risk
    View official trial listing →
  • Recruiting NCT NCT07815067

    A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity

    Not yet reported Novo Nordisk A/S 320 participants Est. completion 2028-06-12 1 site Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Recruiting NCT NCT07855133

    A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication

    Not yet reported Novo Nordisk A/S 60 participants Est. completion 2028-09-06 2 sites Added to GLP-1
    Type 2 diabetes Other conditions: Overweight, Obesity
    View official trial listing →
  • Recruiting NCT NCT07868354

    A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication

    Not yet reported Novo Nordisk A/S 60 participants Est. completion 2028-09-07 2 sites Added to GLP-1
    Type 2 diabetes Other conditions: Overweight, Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07668401

    AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

    Not yet reported Novo Nordisk A/S 400 participants Est. completion 2029-01-11 44 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07861100

    A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

    Not yet reported Novo Nordisk A/S 8500 participants Est. completion 2030-09-16 769 sites Stand-alone
    Other conditions: Cardiovascular Risk, Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Zenagamtide, Zenagamtide injection, Zenagamtide tablet

Related On The Pen coverage

The Weekly Dose & livestreams

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.